Christopher Frankenfield

Route 53 Outlook Google Cloud Hosting Akamai RUM Mobile Friendly Google Analytics WordPress.org New Relic Google Tag Manager Nginx Bootstrap Framework Remote AI

biotechnology immunotherapeutics cancer biotechnology: pharmaceutical preparations health care biotechnology research tumor-selective immunotherapy anti-ctla-4 il-12 tumor-activated therapies solid tumors biologics cytokines antibodies clinical development preclinical development therapeutic index localized treatment tumor microenvironment immune-modulatory molecules gps platform fc-enhanced antibodies tolerability anti-tumor activity checkpoint inhibition monoclonal antibodies cell engagers syngeneic models therapeutic options biopharmaceutical drug discovery phase 1 clinical trials anti-pd-1 novel therapies treatment resistance first-in-human studies clinical validation reproducibility matrix metalloproteases (mmps) systemic side effects effective treatments cancer diagnostics research & development targeted delivery cancer immunotherapeutics tumor-selective activity innovative molecules clinical outcomes radionuclide therapy tumor-activated immuno-oncology precision immunotherapy cancer treatment tumor-selective therapies masked bispecifics t cell engagers proprietary platform technology clinical-stage biotechnology hematologic malignancies immune system activation systemic toxicity reduction investigational therapies fc-enhanced monoclonal antibodies il-2 engineered il-12 cancer patient outcomes oncology research targeted therapeutic innovation biotechnology sector immunotherapy pipeline patient-centric cancer treatment collaboration with abbvie advanced solid tumors colorectal cancer prostate cancer lung cancer matrix metalloproteases clinical trials cancer immunotherapy health wellness & fitness hospital & health care